IMUX NASDAQ
Immunic, Inc.
1W: -14.9%
1M: -44.1%
3M: -46.4%
YTD: +36.5%
1Y: -17.1%
3Y: -45.5%
5Y: -91.4%
$7.96
-0.68 (-7.87%)
Weekly Expected Move ±10.2%
$6
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
Immunic, Inc. $IMUX Shares Sold by State Street Corp
HC Wainwright Predicts Immunic’s Q3 Earnings (NASDAQ:IMUX)
Immunic Q3 EPS Boosted by Brookline Capital Markets
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LP
Immunic, Inc. (NASDAQ:IMUX) Receives $47.57 Consensus PT from Analysts
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy
Immunic announces 1-for-10 reverse stock split
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $5.64
Immunic (NASDAQ:IMUX) Shares to Reverse Split on Monday, April 27th
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
12 Health Care Stocks Moving In Tuesday's After-Market Session
Immunic regains compliance with Nasdaq minimum bid price requirement
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets
Immunic garners new Buy at Guggenheim on lead asset
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of “Buy” by Brokerages
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Research Analysts Set Expectations for Immunic Q1 Earnings
Immunic GAAP EPS of -$0.62 beats by $0.05
Immunic sets stage for phase 3 MS data readout after $400M financing
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Analysts
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
Leading bank calls AI threat to enterprise software "illogical," upgrades five stocks for 2026
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
Wall Street 's mixed signals. Dow set for positive start as Nasdaq and S&P mark time
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic targets MS market with Phase 3 data - ICYMI
Immunic looks to 2026 data as late-stage MS program advances
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic looks to 2026 data as late-stage MS program advances
Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy?
Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Immunic's long-term treatment hope for multiple sclerosis – ICYMI
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December